知镜 Cognispect · 医学文献与研究工作台

Bladder metastasis from cutaneous melanoma during adjuvant immunotherapy: A case report and literature review

Marafioti M, Musarra M, Pepe L, et al.
Mol Clin Oncol · 2026-10-20 · PMID 42973940

文献摘要

Cutaneous melanoma is among the most common malignancies in the United States and accounts for ~5% of all cancers. Melanoma preferentially metastasizes to lymph nodes, lungs, liver and brain, while bladder involvement is rare and associated with poor prognosis. The present study reports a 79-year-old woman with stage III, operable, BRAF wild-type melanoma of the back, treated with surgical excision and adjuvant immunotherapy. During adjuvant pembrolizumab treatment, a first solitary pulmonary relapse was observed. The metastasis was amenable to surgical resection, and the patient continued immunotherapy. Subsequently, recurrent haematuria led to the identification of a bladder lesion, which was removed via transurethral resection and the pathological evaluation confirmed metastatic melanoma. Following this second relapse, restaging imaging documented systemic disease progression involving lymph nodes, liver and bone. The patient then initiated first-line treatment with nivolumab and ipilimumab, achieving an ongoing clinical and radiological partial response. This study highlights several clinically relevant aspects: The potential role of local treatment strategies for oligoprogressive disease in prolonging the benefit of immunotherapy, the rare occurrence of bladder metastasis during adjuvant pembrolizumab, and the activity of combined cytotoxic T-lymphocyte-associated protein 4/programmed cell death protein 1 (PD-1) blockade even after progression on prior anti-PD-1 therapy. Early recognition of atypical metastatic sites and multidisciplinary management may contribute to prolonged disease control in selected patients with metastatic melanoma.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。